Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

被引:127
|
作者
Thiele, Juergen [1 ]
Kvasnicka, Hans Michael [1 ]
Muellauer, Leonhard [2 ]
Buxhofer-Ausch, Veronika [3 ]
Gisslinger, Bettina [3 ]
Gisslinger, Heinz [3 ]
机构
[1] Univ Cologne, Inst Pathol, D-50924 Cologne, Germany
[2] Med Univ Vienna, Inst Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; WORLD-HEALTH-ORGANIZATION; BONE-MARROW BIOPSY; CHRONIC MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA-VERA; DIAGNOSTIC-CRITERIA; INTEROBSERVER RELIABILITY; DIFFERENTIAL-DIAGNOSIS; PROGNOSTIC-FACTORS; NEOPLASMS;
D O I
10.1182/blood-2010-07-293761
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Controversy persists regarding the role of histopathology in the distinction between essential thrombocythemia (ET) and early-prefibrotic primary myelofibrosis (PMF) presenting with thrombocythemia. To investigate the impact and reproducibility of bone marrow (BM) morphology according to the World Health Organization classification, 295 patients with the presumptive clinical diagnosis of either ET or early PMF were studied. Data of this cohort (Vienna group) were compared with 732 corresponding patients (Cologne group). Evaluating blindly (only age and gender known) BM specimens, the 2 groups of pathologists achieved an overall consensus of 78% regarding the total series and 88% concerning the discrimination between ET versus PMF. In 126 ET and 81 early PMF patients without pretreatment and complete documentation, a 90% concordance with the independently established clinical diagnosis was found. In 12 patients, overlapping of histopathology and some clinical findings between ET and polycythemia vera occurred. Contrasting ET, early PMF showed significant differences of presenting hematologic data and an unfavorable prognosis (estimated mean survival, 14 vs 21 years). Comparison of clinical and survival data of the Vienna cohort with the historical Cologne series revealed an overall congruence. This study highlights the impact of BM morphology for the differentiation between true vs false ET. (Blood. 2011; 117(21): 5710-5718)
引用
收藏
页码:5710 / 5718
页数:9
相关论文
共 50 条
  • [31] The Evolving Understanding of Prognosis in Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis
    Masarova, Lucia
    Verstovsek, Srdan
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 299 - 307
  • [32] MicroRNA Expression and JAK2 Allele Burden in Bone Marrow Trephine Biopsies of Polycythemia Vera, Essential Thrombocythemia and Early Primary Myelofibrosis
    Gebauer, Niklas
    Bernard, Veronica
    Gebauer, Wolfgang
    Feller, Alfred C.
    Merz, Hartmut
    ACTA HAEMATOLOGICA, 2013, 129 (04) : 251 - 256
  • [33] MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis
    Ponce, Cesar Cilento
    Chauffaille, Maria de Lourdes F.
    Ihara, Silvia Saiuli M.
    Silva, Maria Regina R.
    LEUKEMIA RESEARCH, 2012, 36 (01) : 93 - 97
  • [34] Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
    Finazzi, G.
    Carobbio, A.
    Thiele, J.
    Passamonti, F.
    Rumi, E.
    Ruggeri, M.
    Rodeghiero, F.
    Randi, M. L.
    Bertozzi, I.
    Vannucchi, A. M.
    Antonioli, E.
    Gisslinger, H.
    Buxhofer-Ausch, V.
    Gangat, N.
    Rambaldi, A.
    Tefferi, A.
    Barbui, T.
    LEUKEMIA, 2012, 26 (04) : 716 - 719
  • [35] JAK2V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis
    Hussein, Kais
    Bock, Oliver
    Theophile, Katharina
    von Neuhoff, Nils
    Buhr, Thomas
    Schlue, Jerome
    Buesche, Guntram
    Kreipe, Hans
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (10) : 1186 - 1193
  • [36] Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision Medicine
    Tashkandi, Hammad
    Younes, Ismail Elbaz
    CANCERS, 2024, 16 (09)
  • [37] CLINICAL RECOMMENDATIONS FOR DIAGNOSIS AND THERAPY OF Rh-NEGATIVE MYELOPROLIFERATIVE DISEASES (POLYCYTHEMIA VERA, ESSENTIAL THROMBOCYTHEMIA, PRIMARY MYELOFIBROSIS)
    Melikyan, A. L.
    Turkina, A. G.
    Abdulkadyrov, K. M.
    Zaritsky, A. Yu
    Afanasyev, B., V
    Shuvaev, V. A.
    Lomaia, E. G.
    Morozova, E., V
    Baikov, V. V.
    Golenkov, A. K.
    Subortseva, I. N.
    Sokolova, M. A.
    Kovrigina, A. M.
    Martynkevich, I. S.
    Gritsaev, S., V
    Sudarikov, A. B.
    Sukhanova, G. A.
    Ivanova, V. L.
    Kaplanov, K. D.
    Konstantinova, T. S.
    Pospelova, T., I
    Ageeva, T. A.
    Shatokhin, Yu., V
    Saychenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2014, 59 (04): : 31 - 56
  • [38] Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
    Lucijanic, Marko
    Krecak, Ivan
    Soric, Ena
    Sabljic, Anica
    Galusic, Davor
    Holik, Hrvoje
    Perisa, Vlatka
    Peric, Martina Moric
    Zekanovic, Ivan
    Kusec, Rajko
    LEUKEMIA RESEARCH, 2022, 119
  • [39] Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
    Hasserjian, Robert P.
    CURRENT CANCER THERAPY REVIEWS, 2012, 8 (01) : 14 - 29
  • [40] Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
    Tefferi, A.
    Saeed, L.
    Hanson, C. A.
    Ketterling, R. P.
    Pardanani, A.
    Gangat, N.
    LEUKEMIA, 2017, 31 (12) : 2851 - 2852